Skip to results

Area of interest

Area of interest

Type (1 selected)


Guidance programme

Showing 126 to 150 of 312

Guidance and quality standards awaiting development
Iptacopan for treating complement 3 glomerulopathy TS ID 10435Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker TS ID 12000Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Technology appraisal guidance
Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux diseaseInterventional procedures guidance
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmiasInterventional procedures guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652Technology appraisal guidance
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer TS ID 10203Technology appraisal guidance
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis TS ID 10136Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]Technology appraisal guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidance
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946Technology appraisal guidance
Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All